October 22, 2009 - Swissmedic, the Swiss Agency for Therapeutic Products, released its report regarding the increased risk of thromboembolism for Yaz and Yasmin users. Swissmedic's Human Medicines Expert Committee analyzed recent data and studies on these risk factors. The agency took particular notice of two epidemiological studies released in August 2009. These studies reported an increased risk of pulmonary embolism, deep vein thrombosis, stroke and heart attack due to the progestin, drosperinone, in Yaz and Yasmin. The agency concluded that the risk of having a venous thromboembolism with a drosperinone-containing birth control pill is close to the risk with 3rd generation birth control pills. So called 2nd generation oral contraceptives remain the safest on the market.
Swissmedic will include the results and findings of their investigation in the patient information included with Yaz and Yasmin birth control pills. Doctors will be warned that they should be cautious when prescribing these pills to patients with any other risk factors for venous thromboembolism such as smoking, obesity and genetic predisposition.
Bayer has attempted to interpret Swissmedic's report in its favor. However, a careful reading of the report indicates that Yaz and Yasmin risks are more in line with those of 3rd generation oral contraceptives. It is well-documented that 3rd generation oral contraceptives carry a statistically significant increased risk of venous thromboembolism compared to other birth control pills.
Bayer now faces hundreds of lawsuits filed by women seriously injured by Yaz and Yasmin. Contact the attorneys at Jackson Allen Williams, LLP if you or a loved one was seriously injured by these birth control pills.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment